BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15713379)

  • 1. N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.
    Rossello A; Nuti E; Carelli P; Orlandini E; Macchia M; Nencetti S; Zandomeneghi M; Balzano F; Uccello Barretta G; Albini A; Benelli R; Cercignani G; Murphy G; Balsamo A
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1321-6. PubMed ID: 15713379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).
    Rossello A; Nuti E; Orlandini E; Carelli P; Rapposelli S; Macchia M; Minutolo F; Carbonaro L; Albini A; Benelli R; Cercignani G; Murphy G; Balsamo A
    Bioorg Med Chem; 2004 May; 12(9):2441-50. PubMed ID: 15080939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase.
    Kim YM; Jang JW; Lee OH; Yeon J; Choi EY; Kim KW; Lee ST; Kwon YG
    Cancer Res; 2000 Oct; 60(19):5410-3. PubMed ID: 11034081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis.
    Yamakawa S; Asai T; Uchida T; Matsukawa M; Akizawa T; Oku N
    Cancer Lett; 2004 Jul; 210(1):47-55. PubMed ID: 15172120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
    Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
    J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.
    Rossello A; Nuti E; Catalani MP; Carelli P; Orlandini E; Rapposelli S; Tuccinardi T; Atkinson SJ; Murphy G; Balsamo A
    Bioorg Med Chem Lett; 2005 May; 15(9):2311-4. PubMed ID: 15837315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
    Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
    Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.
    Nuti E; Orlandini E; Nencetti S; Rossello A; Innocenti A; Scozzafava A; Supuran CT
    Bioorg Med Chem; 2007 Mar; 15(6):2298-311. PubMed ID: 17276072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.
    Breuer E; Salomon CJ; Katz Y; Chen W; Lu S; Röschenthaler GV; Hadar R; Reich R
    J Med Chem; 2004 May; 47(11):2826-32. PubMed ID: 15139760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
    Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.
    Fobian YM; Freskos JN; Barta TE; Bedell LJ; Heintz R; Kassab DJ; Kiefer JR; Mischke BV; Molyneaux JM; Mullins P; Munie GE; Becker DP
    Bioorg Med Chem Lett; 2011 May; 21(10):2823-5. PubMed ID: 21493063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
    Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
    Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct modes of collagen type I proteolysis by matrix metalloproteinase (MMP) 2 and membrane type I MMP during the migration of a tip endothelial cell: insights from a computational model.
    Karagiannis ED; Popel AS
    J Theor Biol; 2006 Jan; 238(1):124-45. PubMed ID: 16005020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel series of highly selective inhibitors of MMP-3.
    Whitlock GA; Dack KN; Dickinson RP; Lewis ML
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationship of hydroxamate-based inhibitors on membrane-bound Fas ligand and TNF-alpha processing.
    Yamamoto M; Hirayama R; Naruse K; Yoshino K; Shimada A; Inoue S; Kayagaki N; Yagita H; Okumura K; Ikeda S
    Drug Des Discov; 1999 Aug; 16(2):119-30. PubMed ID: 10533808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
    Jani M; Tordai H; Trexler M; Bányai L; Patthy L
    Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sultam hydroxamates as novel matrix metalloproteinase inhibitors.
    Cherney RJ; Mo R; Meyer DT; Hardman KD; Liu RQ; Covington MB; Qian M; Wasserman ZR; Christ DD; Trzaskos JM; Newton RC; Decicco CP
    J Med Chem; 2004 Jun; 47(12):2981-3. PubMed ID: 15163180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.
    Moroy G; Denhez C; El Mourabit H; Toribio A; Dassonville A; Decarme M; Renault JH; Mirand C; Bellon G; Sapi J; Alix AJ; Hornebeck W; Bourguet E
    Bioorg Med Chem; 2007 Jul; 15(14):4753-66. PubMed ID: 17512742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of matrix metalloproteinase inhibitors against epidermal basement membrane damage: skin equivalents partially mimic photoageing process.
    Amano S; Ogura Y; Akutsu N; Matsunaga Y; Kadoya K; Adachi E; Nishiyama T
    Br J Dermatol; 2005 Dec; 153 Suppl 2():37-46. PubMed ID: 16280020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and preliminary evaluation of novel pyrrolidine derivatives as matrix metalloproteinase inhibitors.
    Cheng XC; Wang Q; Fang H; Tang W; Xu WF
    Eur J Med Chem; 2008 Oct; 43(10):2130-9. PubMed ID: 18362041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.